Circular of Information for the Use of Cellular Therapy Products (Circular) Resource

Overview of Changes from July 2016 Circular to October 2018 Circular

NOTE: This update includes additional edits, not mentioned below, such as grammatical, organizational updates, and other edits to content. Not all edits are listed below, the Circular should be reviewed in its entirety.

1. In the “Donors” section, clarified that the cord blood donor is the baby/infant.
   a. The baby/infant is the donor of the cord blood product, not the mother. For cord blood products, the health history questionnaire is administered to the birth mother but she is not the donor.

2. In the “HPC, Cord Blood” section, inserted the language, “HPC(CB) products that are not red blood cell (RBC) reduced and are ABO incompatible, should be cautiously evaluated for further processing to reduce the amount of incompatible RBCs in the final product before infusion.”

3. In the “Cellular Therapy Product Descriptions, Actions” section, updated the language in the first sentence to clarify the action of HPCs is to restore hematopoiesis.

4. In the “Instructions for Storage and Administration of Cellular Therapy Products” section, updated the first bullet point to clarify language on regulations and standards-setting organizations. This included inserting the language, “All products must be maintained in a controlled environment and stored under appropriate conditions as described in FDA regulations and applicable regulations required by local and national authorities as well as relevant standard-setting and/or accreditation agencies.” (Bold words are the new insertions).

5. In the “Storage” section, various edits were included such as:
   a. Adding in the language, “It is the responsibility of the facility providing storage to institute measures to maintain conditions that will prevent mix-ups, contamination, and cross-contamination of cellular therapy products, supplies, and reagents (CFR 1271.260).”

6. In the “Cellular Therapy Product Labeling and Supporting Documents” section, clarified that the ABO group and Rh (D) type is required for the donor and for the cord blood product.

7. In the “Nonimmunologic Complications, DMSO Toxicity” section, clarified language such as (bold words are new insertions):
   a. “Removing DMSO from the product by washing the cells before administration to recipients with significant renal and cardiac disease may reduce the risk of symptoms.”
   b. “It is not generally required to wash every thawed cellular product because doing so may result in unintended cell loss.”
c. “Cord blood units that were not RBC depleted prior to cryopreservation should be washed before administration to the recipient.”

8. In the “Nonimmunologic Complications, Septic Infusion Reactions” section, clarified the onset fever temperature as > 1 C rise in temperature during or immediately after product administration should suggest the possibility of bacterial contamination and/or the presence of endotoxin in the product.

9. In the “Reporting of Adverse Reactions” section, added in information on centralized databases for collecting adverse reactions (e.g. CIBMTR, WMDA).

10. In Table 1A:
   a. West Nile Virus (WNV) was added to the table.
   b. Updated some language in the footnotes and a reference.

11. In Table 1B:
   a. Changed previous language, “up to 30 days before collection” to “within 30 days before donation.” (Bold words indicate new insertions).
   b. Inserted additional reference and clarifying information.